142 related articles for article (PubMed ID: 19126249)
1. Identifying patient-relevant endpoints among individuals with schizophrenia: an application of patient-centered health technology assessment.
Kinter ET; Schmeding A; Rudolph I; dosReis S; Bridges JF
Int J Technol Assess Health Care; 2009 Jan; 25(1):35-41. PubMed ID: 19126249
[TBL] [Abstract][Full Text] [Related]
2. Designing pain research from the patient's perspective: what trial end points are important to patients with chronic pain?
Casarett D; Karlawish J; Sankar P; Hirschman K; Asch DA
Pain Med; 2001 Dec; 2(4):309-16. PubMed ID: 15102235
[TBL] [Abstract][Full Text] [Related]
3. Integrating patients' views into health technology assessment: Analytic hierarchy process (AHP) as a method to elicit patient preferences.
Danner M; Hummel JM; Volz F; van Manen JG; Wiegard B; Dintsios CM; Bastian H; Gerber A; Ijzerman MJ
Int J Technol Assess Health Care; 2011 Oct; 27(4):369-75. PubMed ID: 22004779
[TBL] [Abstract][Full Text] [Related]
4. Constructive Technology Assessment (CTA) as a tool in coverage with evidence development: the case of the 70-gene prognosis signature for breast cancer diagnostics.
Retèl VP; Bueno-de-Mesquita JM; Hummel MJ; van de Vijver MJ; Douma KF; Karsenberg K; van Dam FS; van Krimpen C; Bellot FE; Roumen RM; Linn SC; van Harten WH
Int J Technol Assess Health Care; 2009 Jan; 25(1):73-83. PubMed ID: 19126254
[TBL] [Abstract][Full Text] [Related]
5. Patient-based health technology assessment: a vision of the future.
Bridges JF; Jones C
Int J Technol Assess Health Care; 2007; 23(1):30-5. PubMed ID: 17234014
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic alliance, a stake in schizophrenia].
Charpentier A; Goudemand M; Thomas P
Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
[TBL] [Abstract][Full Text] [Related]
7. Conditionally funded field evaluations and practical trial design within a health technology assessment framework.
Bowen JM; Patterson LL; O'Reilly D; Hopkins RB; Blackhouse G; Burke N; Xie F; Tarride JE; Goeree R
J Am Coll Radiol; 2009 May; 6(5):324-31. PubMed ID: 19394573
[TBL] [Abstract][Full Text] [Related]
8. Doctor-patient communication in glaucoma care: analysis of videotaped encounters in community-based office practice.
Friedman DS; Hahn SR; Quigley HA; Kotak S; Kim E; Onofrey M; Eagan C; Mardekian J
Ophthalmology; 2009 Dec; 116(12):2277-85.e1-3. PubMed ID: 19744715
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study.
Kobylecki CJ; Jakobsen KD; Hansen T; Jakobsen IV; Rasmussen HB; Werge T
Neuropsychobiology; 2009; 59(4):222-6. PubMed ID: 19521114
[TBL] [Abstract][Full Text] [Related]
10. Subjective side effects of antipsychotics and medication adherence in people with schizophrenia.
McCann TV; Clark E; Lu S
J Adv Nurs; 2009 Mar; 65(3):534-43. PubMed ID: 19222651
[TBL] [Abstract][Full Text] [Related]
11. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
Wallner PE; Konski A
J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
[TBL] [Abstract][Full Text] [Related]
12. Methods of synthesizing qualitative research studies for health technology assessment.
Ring N; Jepson R; Ritchie K
Int J Technol Assess Health Care; 2011 Oct; 27(4):384-90. PubMed ID: 22004781
[TBL] [Abstract][Full Text] [Related]
13. Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.
Barbui C; Kikkert M; Mazzi MA; Becker T; Bindman J; Schene A; Nosè M; Helm H; Thornicroft G; Tansella M
Psychopathology; 2009; 42(5):311-7. PubMed ID: 19672133
[TBL] [Abstract][Full Text] [Related]
14. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Velligan DI; Weiden PJ; Sajatovic M; Scott J; Carpenter D; Ross R; Docherty JP;
J Clin Psychiatry; 2009; 70 Suppl 4():1-46; quiz 47-8. PubMed ID: 19686636
[TBL] [Abstract][Full Text] [Related]
15. Endpoints in medical communication research, proposing a framework of functions and outcomes.
de Haes H; Bensing J
Patient Educ Couns; 2009 Mar; 74(3):287-94. PubMed ID: 19150197
[TBL] [Abstract][Full Text] [Related]
16. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
Leucht S; Kissling W; Davis JM
Psychol Med; 2009 Oct; 39(10):1591-602. PubMed ID: 19335931
[TBL] [Abstract][Full Text] [Related]
17. Exploring subjective outcomes perceived by patients receiving a pharmaceutical care service.
Renberg T; Lindblad AK; Tully MP
Res Social Adm Pharm; 2006 Jun; 2(2):212-31. PubMed ID: 17138509
[TBL] [Abstract][Full Text] [Related]
18. [Cognitive remediation and cognitive assistive technologies in schizophrenia].
Sablier J; Stip E; Franck N
Encephale; 2009 Apr; 35(2):160-7. PubMed ID: 19393385
[TBL] [Abstract][Full Text] [Related]
19. Explicit versus implicit review to explore combination antipsychotic prescribing.
Wheeler A
J Eval Clin Pract; 2009 Aug; 15(4):685-91. PubMed ID: 19674220
[TBL] [Abstract][Full Text] [Related]
20. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
Volavka J; Citrome L
Expert Opin Pharmacother; 2009 Aug; 10(12):1917-28. PubMed ID: 19558339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
